DPCO List August 2020

The 77th Authority Meeting held on 06.08.2020 where NPPA fixed the retail price of 29 formulations, under Drug (price control) Order 2013. This is the first DPCO list August 2020, main including’s in the 29 formulation list are Memantine Hydrochloride + Donepezil Hydrochloride tablet, Rosuvastatin+ Clopidogrel Capsule Rosuvastatin+ Aspirin + Clopidogrel Capsule,  Metronidazole ER Tablet, Desvenlafaxine ER + Clonazepam Tablet (MDD-XR Plus 50), Desvenlafaxine ER + Clonazepam Tablet (MDD-XR Plus 100), Glimepiride + Metformin Tablet (MyGainPro 2), Amlodipine +Atenolol Tablet (MyAdol), Amlodipine + Losartan Potassium Tablet (MyLosdro A), Calcium Carbonate +Vitamin D3 Tablet (MyVitacillin) and Metoprolol + Cilnidipine Tablet

Some more formulations are which of DPCO price have fixed Tolperisone SR + Diclofenac Tablet, Dexamethasone Tablet, Metoprolol PR + Cilnidipine Tablet, Paracetamol + Mefenamic Acid suspension (Sumo-L Plus DS), Bisoprolol + Amlodipine Tablet,  Mesalazine Suppository, Glimepiride + Voglibose + Metformin Hydrochloride Tablet, Capecitabine + Cyclophosphamide Tablet, Methylcobalamin + Alpha Lipoic Acid + Pyridoxine + Folic Acid Capsule (MyFocoly), Folic Acid+ Methylcobalamin + Pyridoxine Hydrochloride Tablet and Chlorhexidine Gluconate + Isopropyl Alcohol Topical Solution. This list corresponds to the manufacturer and supplier name.

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, 20th August, 2020

ORDER S. O. 2822(E) In exercise of the powers conferred by paragraphs 5, 11, and 15 of The Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

DPCO List August 2020

[table id=18 responsive=scroll/]

Note:

(a) The manufacturer of the above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

 (e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Related Posts :

Darshan Singh

The author has 20 years of experience in the Pharmaceutical Manufacturing Companies. Have exposure to all audit documents for WHO-GMP, PIC/S, USFDA, Export documents, US-FDA documents, Validation of Pharma machinery, and Quality Control Instruments. Expert in Pharma Plant Setup and sale and acquisition of running pharma company.

https://www.laafon.com
× How can I help you?